Considering Early Detection of Relapsed Ovarian Cancer
- 1 July 2011
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 21 (5), 837-845
- https://doi.org/10.1097/igc.0b013e31821bb88c
Abstract
Patients treated for ovarian cancer with curative intent receive an intensive follow-up program in the years after treatment. However, the aimed improved survival through early detection of recurrence is subject to debate. Theoretically, the survival benefit depends on the lead time and the preclinical detection rate and on the effectiveness of recurrence treatment. This systematic review aimed at determining the effectiveness of early detection of recurrent ovarian cancer. A systematic literature search in PubMed, EMBASE, MEDLINE, and the Cochrane Library was performed for articles published in 1985 to 2009 in English, German, or Dutch, excluding editorials, letters, and case reports. In total, 67 articles were included. Of 4 observational studies and 1 randomized controlled trial, only 1 observational study reported a better survival for patients who attended routine follow-up compared with those who did not. The sensitivity of cancer antigen 125 for a preclinical recurrence, based on 38 articles using 35 U/mL as a cutoff level, was 65%, with a median lead time of 3 months (range, 1-7 months). Seven studies showed that, on average, 67% (ranging from 20% to 80%) of the 798 relapsed patients had no clinical symptoms when recurrent ovarian cancer was diagnosed. Routine follow-up may detect 2 of 3 recurrences asymptomatically with a lead time of 3 months. Recurrence treatment may extend survival by several months, but published studies did not show a survival advantage of early detection by routine follow-up examinations. Therefore, the content and aims of routine follow-up should be reconsidered, whereas routine cancer antigen 125 testing with the aim to improve life expectancy should be omitted.Keywords
This publication has 19 references indexed in Scilit:
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialThe Lancet, 2010
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Sister Mary Joseph's Nodule As a Diagnostic Clue to Metastatic Colon CarcinomaJournal of Clinical Oncology, 2009
- Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?: A Retrospective Italian Multicentric StudyInternational Journal of Gynecologic Cancer, 2009
- Patients' views of follow-up after treatment for gynaecological cancerJournal of Obstetrics and Gynaecology, 2009
- The role of regular physical examination in the detection of ovarian cancer recurrenceGynecologic Oncology, 2008
- Optimal Chemotherapy Treatment for Women with Recurrent Ovarian CancerCurrent Oncology, 2007
- Follow-up of ovarian and primary peritoneal carcinoma: The value of physical examination in patients with pretreatment elevated CA125 levelsGynecologic Oncology, 2006
- Mode of detection of recurrent gynecological malignancy: does routine follow-up delay diagnosis and treatment?International Journal of Gynecologic Cancer, 2006
- Post-therapy surveillance and after-care in ovarian cancerEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2004